Daily Cardiology Research Analysis
Analyzed 157 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stood out today: a Nature Medicine study identifies the serum NOTCH3 extracellular domain as a robust biomarker for idiopathic pulmonary arterial hypertension; a Communications Medicine analysis shows that accelerated biological ageing markedly raises abdominal aortic aneurysm risk, especially when combined with high genetic risk; and a Heart Rhythm meta-analysis suggests oral anticoagulants may be safely discontinued after atrial fibrillation ablation in selected low-risk patients, reducing major bleeding, but not in those at high thromboembolic risk.
Research Themes
- Circulating biomarkers for cardiovascular diseases
- Biological ageing and genetic risk in vascular disease stratification
- Anticoagulation strategies after atrial fibrillation ablation
Selected Articles
1. The NOTCH3 extracellular domain is a serum biomarker for pulmonary arterial hypertension.
Across three independent cohorts, serum NOTCH3-ECD concentrations were significantly elevated in patients with idiopathic pulmonary arterial hypertension compared with healthy individuals, supporting its role as a circulating biomarker. The findings align mechanistically with constitutive NOTCH3 cleavage in IPAH lungs and suggest utility for diagnosis and potentially for disease monitoring.
Impact: This study identifies and validates a mechanistically grounded serum biomarker for IPAH across multiple cohorts, addressing a major diagnostic gap in a lethal disease. Publication in Nature Medicine underscores the methodological rigor and translational potential.
Clinical Implications: NOTCH3-ECD could complement current diagnostic pathways for pulmonary arterial hypertension, enabling noninvasive screening and longitudinal monitoring. Thresholds, assay standardization, and prospective evaluation in at-risk populations will be key for clinical adoption.
Key Findings
- Serum NOTCH3-ECD levels were significantly higher in IPAH versus healthy controls across three geographically distinct cohorts.
- The biomarker is mechanistically linked to constitutive NOTCH3 cleavage in IPAH lungs, supporting biological plausibility.
- Results suggest potential roles in diagnosis and disease monitoring of pulmonary arterial hypertension.
Methodological Strengths
- Multi-cohort, geographically diverse validation with substantial sample size
- Mechanistic coherence with disease biology (NOTCH3 cleavage)
Limitations
- Observational design precludes causal inference
- Assay thresholds and external clinical validation for monitoring remain to be established
Future Directions: Prospective studies defining diagnostic thresholds, test performance against contemporary standards (e.g., right heart catheterization), and responsiveness to therapy will clarify clinical utility. Evaluation in related PH subtypes is warranted.
New biomarkers are needed to detect and follow individuals with World Health Organization group 1.1 pulmonary hypertension (idiopathic pulmonary arterial hypertension (IPAH)). As NOTCH3 cleavage occurs constitutively in the lungs of individuals with IPAH, we investigated whether the NOTCH3 extracellular domain (NOTCH3-ECD) shed into serum could be used as a robust biomarker for IPAH. In three geographically distinct cohorts comprising 341 individuals with IPAH (267 women, 74 men) and 376 healthy individuals (278 women, 98 men), serum NOTCH3-ECD levels were significantly higher in individuals with IPAH (mean ± s.d.: 19.9 ± 5.5 ng ml
2. Associations of biological ageing and genetic risk with incident abdominal aortic aneurysm.
In over 350,000 UK Biobank participants, accelerated biological ageing measured by KDMAge and PhenoAge predicted higher incident AAA risk, with the strongest risk observed when combined with high polygenic risk. Findings support biological age as a meaningful risk construct for AAA beyond chronological age.
Impact: This work integrates biomarker-derived biological ageing metrics with genetic risk to refine AAA risk prediction at population scale, offering a path toward precision prevention.
Clinical Implications: Biological age estimation, particularly combined with polygenic risk scores, could guide targeted AAA surveillance and preventive strategies beyond chronological age-based screening policies.
Key Findings
- Accelerated biological ageing (KDMAge HR 1.29; PhenoAge HR 1.63) was associated with increased incident AAA risk.
- Joint exposure to accelerated biological ageing and high genetic risk yielded the highest AAA risk (e.g., PhenoAge HR 2.72).
- Significant additive interaction was observed between PhenoAge acceleration and high genetic risk.
Methodological Strengths
- Very large, well-characterized population cohort with standardized measurements
- Use of two independent biological ageing algorithms and polygenic risk integration
Limitations
- Observational retrospective design with potential residual confounding and selection bias (UK Biobank)
- Lack of interventional data to show modifiability of biological age for AAA prevention
Future Directions: Test whether modifying biological ageing metrics through targeted interventions reduces AAA incidence; validate models across diverse populations and evaluate cost-effectiveness for screening.
BACKGROUND: Abdominal aortic aneurysm (AAA) is a degenerative cardiovascular disorder prevalent with ageing. While accelerated biological ageing contributes to age-related diseases, its specific role in AAA risk remains unclear. This study investigates the relationships between biological ageing and risk of incident AAA and genetic predisposition to the disease. METHODS: This retrospective study used UK Biobank data from 350,483 participants without AAA at baseline. Biological age was assessed using Klemera-Doubal Method (KDMAge) and phenotypic age (PhenoAge) algorithms. Accelerated biological ageing was determined through residual analysis against chronological age, with values above 0 indicating accelerated ageing. Cox proportional hazards models evaluated the associations of biological age accelerations with AAA risk. Polygenic risk scores were calculated to evaluate genetic predisposition to AAA. We also examined the interactions between biological age accelerations and genetic predisposition on the risk of AAA. RESULTS: Here we show that participants with accelerated biological ageing have an elevated risk of AAA onset compared to those without, with hazard ratios (HRs) of 1.29 (95% CI 1.17-1.42) for KDMAge and 1.63 (95% CI 1.47-1.81) for PhenoAge. For joint associations, participants with accelerated biological ageing and high genetic risk have the highest risk of incident AAA (KDMAge: HR 2.15, 95% CI 1.81-2.54; PhenoAge: HR 2.72, 95% CI 2.26-3.28). There is a significant additive interaction between high genetic risk and accelerated biological ageing of PhenoAge. CONCLUSIONS: Accelerated biological ageing is significantly associated with an increased risk of AAA incidence, suggesting its potential as a focal point for risk assessment and targeted intervention development. Abdominal aortic aneurysm (AAA) is a life-threatening cardiovascular degenerative disease, for which ageing is a non-negligible risk factor. However, the specific role of accelerated biological ageing remains unclear. We investigated this relationship in over 350,000 participants in the UK, measuring biological age using clinical biomarker-based algorithms and assessing its association with future AAA risk, alongside genetic predisposition. We found that accelerated biological ageing significantly increased the risk of developing AAA, with the highest risk observed in individuals who also had high genetic risk. These findings establish biological ageing as a significant risk factor for AAA. Assessing biological age, especially in combination with genetic risk, could help identify at-risk individuals early and guide targeted prevention strategies.
3. Can Oral Anticoagulants Be Safely Discontinued Following Atrial Fibrillation Ablation? A Systematic Review and Meta-Analysis of Reconstructed Time-to-Event Data.
Across 32 studies with 271,808 patients after AF ablation, stopping OAC did not increase overall thromboembolic events or mortality, while significantly reducing major bleeding. However, discontinuation was associated with increased thromboembolic risk in higher-risk subgroups (e.g., elevated CHA2DS2‑VASc), underscoring the need for individualized decisions.
Impact: This comprehensive synthesis with reconstructed time-to-event data directly informs a common post-ablation clinical dilemma, balancing bleeding reduction against thromboembolic risk in stratified groups.
Clinical Implications: Consider OAC discontinuation in carefully selected low thromboembolic risk patients after successful ablation to reduce major bleeding; maintain OAC in high-risk patients (e.g., high CHA2DS2‑VASc). Shared decision-making with rhythm monitoring is essential.
Key Findings
- Overall thromboembolic events and mortality were not significantly different between OAC discontinuation and maintenance after AF ablation (e.g., TE OR 0.90, p=0.47).
- Major bleeding was significantly reduced with OAC discontinuation (OR 0.35, p<0.01).
- In higher-risk subgroups (e.g., elevated CHA2DS2‑VASc), OAC discontinuation was associated with increased thromboembolic risk.
Methodological Strengths
- Large aggregate sample with 32 studies and reconstructed time-to-event analyses
- Subgroup and sensitivity analyses addressing heterogeneity and risk stratification
Limitations
- Predominance of non-randomized observational data limits causal inference
- Heterogeneity in ablation success definitions, rhythm monitoring, and outcome ascertainment
Future Directions: Prospective randomized or high-quality pragmatic studies by stroke risk strata are needed; integration of continuous rhythm monitoring and left atrial appendage imaging may refine individualized discontinuation strategies.
BACKGROUND: Ablation procedures are frequently employed to restore sinus rhythm in atrial fibrillation (AF), given the increased stroke risk associated with AF. The decision to discontinue oral anticoagulation (OAC) therapy post-procedure requires careful consideration of stroke and bleeding risks, especially due to the absence of definitive guidelines. OBJECTIVE: This meta-analysis aims to evaluate the implications of OAC discontinuation following catheter ablation for AF, focusing on thromboembolic (TE) and bleeding events. METHODS: A systematic search was conducted in four databases, for studies comparing OAC discontinuation with maintenance in AF patient's post-ablation. We pooled odds ratios (OR) for binary outcomes with random-effects model and performed sensitivity analyses with hazard ratios (HR) and subgroups based on CHA RESULTS: Thirty-two studies were included, comprising 271,808 patients, with 88,164 (32.4%) discontinuing OAC. The primary analysis showed no significant differences in TE incidence (OR 0.90; 95% CI: 0.68 to 1.20; p=0.47) or mortality (OR 0.85; 95% CI: 0.67 to 1.08; p=0.19). However, OAC discontinuation was significantly associated with reduced major bleeding events (OR 0.35; p<0.01). For patients with a CHA CONCLUSION: Discontinuation of OACs in AF patient's post-ablation did not significantly affect overall TE incidence but a notable reduction in major bleeding events. However, there was a significant increase in TE risk among patients with CHA